Mr. Rashid Bux reports

BIOMARK DIAGNOSTICS ANNOUNCES LANDMARK PUBLICATION VALIDATING HIGH SPECIFICITY AND ACCURACY OF ITS EARLY-STAGE LUNG CANCER TEST

A pivotal study regarding Biomark Diagnostics Inc.'s metabolomics and machine learning powered technology has been published as part of the special issue of Molecular Pathogenesis and Diagnostics of Lung Diseases of the International Journal of Molecular Sciences. The research, titled "Clinical Validation of Plasma Metabolite Markers for Early Lung Cancer Detection," provides significant external validation for Biomark's metabolomics and machine learning powered technology, particularly highlighting its high specificity and accuracy in detecting early-stage non-small-cell lung cancer and differentiating it from other non-cancerous lung conditions.

The study utilized a large, clinically diverse patient cohort, analyzing 680 archived plasma samples in a discovery cohort and an independent set of 216 plasma samples for validation. A key strength of the research was the composition of the control group, which included not only healthy individuals, but also patients with various non-cancerous lung diseases. This design allowed for a rigorous assessment of the test's ability to accurately identify lung cancer, minimizing the potential for false positives due to other lung conditions.

Dr. Jean-Francois Haince, chief scientific officer of Biomark, commented: "We are exceptionally pleased with these results, which builds upon our previous research using a much larger and more clinically complex patient cohort. The inclusion of patients with non-malignant lung conditions in our control group was crucial for truly testing the specificity of our metabolite panel. The models achieved area under the ROC curve values of over 93 per cent for distinguishing Stage 1-2 NSCLC from the complex control group. The high AUROC values achieved, especially for the earliest stages of lung cancer, confirm the robustness of our metabolomic and machine learning approach. This validation is a significant step forward in advancing our liquid biopsy technology towards broader clinical adoption to aid in early cancer diagnosis and management."

"This publication in a respected peer-reviewed journal is a tremendous milestone for Biomark and a powerful external validation of our team's dedicated work," said Rashid Ahmed Bux, president and chief executive officer of Biomark Diagnostics. "The study's demonstration of high accuracy, particularly its ability to differentiate early-stage cancer from other lung diseases, is critical. It gives us, and the clinical community, greater confidence in our test's potential to become an essential tool in the fight against lung cancer, where early detection is paramount for improving patient survival rates."

The ability to detect lung cancer at its earliest stages significantly improves patient outcomes and survival rates. Current screening methods, such as low dose computed tomography, have limitations, including lower sensitivity and specificity compared with regular CT scans, and can result in false positives leading to unnecessary invasive procedures. Biomark's minimally invasive blood test offers a promising approach to complement current screening methods, potentially leading to earlier interventions and better patient prognoses.

The full publication, "Clinical Validation of Plasma Metabolite Markers for Early Lung Cancer Detection," can be downloaded on the International Journal of Molecular Sciences website.

About Biomark Diagnostics Inc.

Biomark is a leading developer of liquid biopsy tests for the early detection of cancer that leverages the power of metabolomics and machine learning algorithms. The company's proprietary technology utilizes a simple blood draw to detect the presence of cancer-associated biomarkers, enabling earlier diagnosis and improved patient outcomes. The technology can also be used for measuring response to treatment and potentially for serial monitoring of cancer survivors. Biomark is committed to developing innovative and accessible diagnostic solutions to address unmet medical needs in oncology.

We seek Safe Harbor.